Grudziadz

Researchers are studying BI-1206, a monoclonal antibody targeting CD32b, combined with rituximab with or without acalabrutinib, in adults with indolent B-cell Non-Hodgkin Lymphoma NHL that has relapsed or is resistant to rituximab treatment. The trial focuses on specific lymphoma subtypes including follicular lymphoma except grade 3B, marginal zone lymphoma, and mantle cell lymphoma. This Phase 12a trial aims to assess safety, dosing, and preliminary effectiveness. The study has two main parts Phase 1 involves dose escalation with intravenous IV and subcutaneous SC dosing of BI-1206 combined with rituximab to determine the best doses for Phase 2a. Phase 2a includes dose expansion with the selected IV dose, signal-seeking cohorts evaluating BI-1206 with rituximab and acalabrutinib via IV and SC routes, and a dose optimization phase to select the recommended BI-1206 dose in combination with both treatments. Participants will receive treatment during an induction period of 28 days, during which safety and dose-limiting toxicities are closely monitored. Researchers will evaluate adverse events, drug levels, immune responses, and lymphoma response rates up to one year. The study involves biopsies, blood tests, and clinical assessments to track treatment effects and safety. Participants remain under medical observation throughout the trial, with follow-up visits to monitor health and response.

Researchers are evaluating camizestrant against standard endocrine therapy for patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. These patients must have completed locoregional therapy and at least 2 to 5 years of standard adjuvant endocrine therapy. The study is a Phase III open-label trial focused on improving outcomes for these patients over a long-term period. Participants are randomly assigned to receive either camizestrant orally or continue with the standard endocrine therapy chosen by their investigator, which may include aromatase inhibitors exemestane, letrozole, anastrozole or tamoxifen. Treatment in each group lasts for 60 months. The study allows prior use of CDK46 inhibitors and includes a follow-up period extending up to 10 years from the last patient randomization. During the study, participants will undergo regular assessments to monitor invasive breast cancer-free survival and other outcomes such as invasive disease-free survival, distant relapse-free survival, overall survival, and safety. Researchers will also evaluate symptoms like joint pain, hot flushes, and vaginal dryness using specific scales, along with quality of life measures and pharmacokinetics. Safety monitoring continues up to 28 days after the last dose, and participants remain under observation for up to 10 years total.

Researchers are evaluating the safety and effectiveness of induction therapy using Afimkibart also called RO7790121 in people with moderately to severely active ulcerative colitis UC. This Phase III study is designed as a multicenter, double-blind, placebo-controlled trial to compare Afimkibart with a placebo. The study aims to understand how well Afimkibart works to induce remission in UC and its safety profile. Participants will be randomly assigned to one of two groups. One group will receive Afimkibart through an intravenous IV infusion followed by a subcutaneous SC injection, while the other group will receive matching placebo infusions and injections. The treatment period lasts 12 weeks, during which researchers will assess the effects of the therapies. Throughout the study, participants will undergo various assessments including evaluations of clinical remission, endoscopic improvement, histologic changes, and symptom severity at specified time points such as baseline, Week 2, and Week 12. Safety will be monitored by tracking adverse events for up to 30 weeks after starting treatment. The total participation duration spans the treatment and follow-up periods to gather comprehensive data on outcomes and safety.

This research aims to evaluate the long-term safety and explore the efficacy of astegolimab in adults aged 40 to 90 years with chronic obstructive pulmonary disease COPD. It focuses on participants who have completed a 52-week placebo-controlled treatment period in previous studies GB43311 or GB44332. The study is a phase 3, open-label extension to gather extended safety information on this drug in COPD patients. Participants from the parent studies who qualify will receive subcutaneous injections of astegolimab every two weeks throughout the study until it ends. This open-label extension allows all participants to receive the active drug without placebo comparison. The study continues treatment beyond the initial 52-week period to monitor long-term effects. During the study, participants will be monitored for adverse events up to 12 weeks after their last dose of astegolimab. Researchers will collect safety data to understand the incidence of any side effects. The study involves regular assessments and follow-ups to ensure participant well-being, with the total duration lasting until July 2034.

Researchers are evaluating the safety and tolerability of the drug RO7121932 given through intravenous IV and subcutaneous SC injections in adults with multiple sclerosis MS. The study focuses on three parts a single ascending IV dose, a single ascending SC dose, and multiple ascending SC doses, aiming to understand how the body processes this medication. This is a phase 1 trial designed to assess adverse events and other safety measures. Participants receive RO7121932 in three different ways depending on the study part. In Part 1, a single IV dose starting at 7 mg will be given and gradually increased up to 2000 mg, not exceeding 4000 mg. Part 2 involves a single SC dose starting at 70 mg and increased up to 200 mg. Part 3 includes multiple SC doses once weekly from Day 1 to Day 22, starting at 70 mg and increasing up to 700 mg. Dosages may be adjusted based on emerging data. During the study, participants undergo regular monitoring for side effects, including recording adverse events and serious adverse events over several months. Assessments include measuring local injection site reactions, suicide risk, blood and cerebrospinal fluid drug concentrations, immune cell changes, and antibody development. The study may last up to around 6 to 7 months, with multiple visits for safety checks and lab tests to understand how the drug behaves in the body.

Researchers are evaluating the effect of muvalaplin in lowering cardiovascular risks among adults with elevated lipoproteina who either have atherosclerotic cardiovascular disease or are at risk of a first heart attack or stroke. This phase 3, randomized, double-blind study aims to investigate whether muvalaplin can reduce major adverse cardiovascular events compared to placebo in this high-risk population. Participants are randomly assigned to receive either muvalaplin or a placebo, both given orally. The study is designed with parallel groups and will last about 5.25 years, during which the occurrence of cardiovascular events and changes in lipoproteina levels will be closely monitored. Throughout the study, participants will undergo regular assessments including measurement of lipoproteina levels, monitoring of cardiovascular events such as heart attacks or strokes, and evaluation of healthcare resource use. The primary outcome is the time to first major adverse cardiac event, tracked from baseline until the study ends. Safety and pharmacokinetics of muvalaplin will also be evaluated during the trial period.

This research aims to compare the effects of prasugrel combined with low-dose aspirin versus high-dose aspirin alone and low-dose aspirin alone in patients with chronic coronary syndrome undergoing coronary artery bypass grafting CABG. The study is a multicenter, randomized trial focused on evaluating graft failure rates and other cardiovascular outcomes in patients with stable coronary artery disease after CABG. Participants will be randomly assigned to one of three groups prasugrel 10 mg plus low-dose aspirin 75 mg daily, high-dose aspirin 300 mg daily, or low-dose aspirin 75 mg daily. Treatments are administered orally for three months, followed by all groups receiving low-dose aspirin alone. The study monitors graft function and cardiovascular events up to 12 months and beyond. During the study, participants will undergo assessments to evaluate graft failure, ischemic and bleeding events, and quality of life at 6, 12, and 60 months after surgery. The primary outcome is the incidence of graft failure at 12 months comparing the different treatments. Participants will be monitored through clinical follow-ups and evaluations to track treatment effects and safety over time.

Researchers are evaluating the effects of intravenous ferric carboxymaltose FCM compared with a placebo on death risk, heart failure events, NT-proBNP levels, and quality of life in patients who recently had an acute myocardial infarction AMI and have iron deficiency. This phase 4, multicenter, randomized, double-blind, placebo-controlled clinical trial aims to assess these outcomes over a follow-up period ranging from 8 to 36 months. Participants are randomly assigned to receive either an intravenous 15-minute infusion of 1000 mg FCM diluted in saline or a placebo infusion of saline alone. The first dose is given on the day of randomization, with follow-up visits at 4, 8, 12, 18, 24, and 30 months to reassess participants and possibly repeat treatment if safety criteria are met. During the study, participants undergo evaluations including monitoring of death rates, heart failure events such as unplanned hospitalizations or emergency visits, changes in NT-proBNP concentration, and quality of life measured by the EQ-5D questionnaire. Safety and treatment effects are tracked throughout the follow-up period, which can last up to 36 months from the start of participation.

Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD who experience symptoms such as intermittent claudication. This phase 3 trial aims to understand how the drug affects walking ability and symptom relief over a period of about 58 weeks. The study is sponsored by Eli Lilly and Company and involves participants with confirmed PAD and reduced ankle brachial index ABI. Participants are randomly assigned to receive either orforglipron or a placebo in a double-blind design. Participants will take the study drug or placebo orally once daily. The study includes two groups one receiving orforglipron, and the other receiving a placebo. The treatment period lasts for approximately 52 weeks, during which participants will be monitored closely. This design allows comparison of the drugs effects against placebo on walking distance, symptoms, and quality of life measures. During the study, participants will undergo assessments including measuring their maximum walking distance, pain-free walking distance, and performance in a six-minute walk test at baseline and after 52 weeks. Questionnaires evaluating vascular quality of life and blood tests measuring inflammatory markers and blood pressure will also be collected. Safety and symptom relief will be monitored throughout the nearly one-year participation, helping to determine the drugs impact on PAD symptoms and overall vascular health.

Researchers are evaluating the long-term safety and tolerability of NBI-1065845 as an additional treatment for adults with Major Depressive Disorder MDD. This Phase 3, open-label study focuses on participants who have a primary diagnosis of recurrent moderate or severe MDD or persistent depressive disorder and have had an inadequate response to oral antidepressant treatments in their current depressive episode. Participants will receive NBI-1065845 tablets taken orally once daily as an adjunctive therapy alongside their ongoing antidepressant treatments. The study is designed as a single-group, open-label trial without placebo or comparison groups. The treatment period and follow-up extend over 52 weeks, during which safety and tolerability will be closely monitored. Throughout the study, participants will be assessed for treatment-emergent adverse events TEAEs from baseline through Week 52. Participants must be willing and able to comply with all study procedures and restrictions, including regular visits and evaluations determined by the investigators. The overall study duration allows for comprehensive monitoring of safety outcomes and participant well-being.